This is issue #1 of Compounded. An anonymous brief on how cash-pay healthcare actually gets built. Every claim sourced. Every operator gets right of reply.Full piece, 16 citations, the scenario math:
https://t.co/LwQqVOs7f6
The FDA committee reviewing 7 peptides on July 23 (BPC-157, TB-500, Epitalon + more) has recommended ZERO of its first twelve substance reviews for approval.
Twelve to nothing.
The longevity industry is pricing in a 70% yes. 🧵
So the trade isn't "the vote fails." It's that July 23 changes far less, far slower than the people betting on it think.
Could we be wrong? ~25-30%. But even a yes doesn't make one peptide legal in 2026. To lose this you need the FDA to move fast. It never has.